非诺贝特治疗中心性浆液性脉络膜视网膜病变的临床研究

发布时间：2018-03-14 17:02

本文选题：非诺贝特　切入点：视力　出处：《眼科新进展》2014年04期 　论文类型：期刊论文

【摘要】：目的观察非诺贝特治疗中心性浆液性脉络膜视网膜病变的(central serous chorioretinopathy,CSC)临床疗效。方法 72例(72眼)CSC患者随机分为两组,对照组(36例36眼)口服安慰剂维生素C片0.1 g,每日3次,试验组36例(36眼)口服非诺贝特胶囊0.2 g,每日3次,饭前0.5 h口服,连续用28 d,比较观察患者治疗前后视力、眼底镜检查、眼底荧光血管造影检查及光学相干断层扫描的变化。结果两组患者一般情况比较差异均无统计学意义(均为P0.05);治疗28 d后,两组药物对甘油三酯、低密度脂蛋白影响的比较差异均有统计学意义(均为P0.05);视力提高或无变化53眼,其中对照组21眼(39.6%),试验组32眼(60.4%),两组视力与治疗前比较差异有统计学意义(χ2=8.651,P0.05)。对照组治愈率为16.7%,总有效率58.3%;试验组治愈率66.7%,总有效率88.9%;两组总有效率比较差异有统计学意义(χ2=24.669,P0.05)。治疗后2周和4周,试验组视网膜脱离面积减小为(123 221±86 431)μm2、(43 246±34 321)μm2,减小幅度大于对照组(213 241±102 548)μm2、(1521 245±87 326)μm2,差异均有统计学意义意义(均为P0.05),两组均无不良反应发生。结论非诺贝特可提高CSC患者视力,有效改善CSC症状,缩短治疗时间。
[Abstract]:Objective to observe the clinical effect of fenofibrate in the treatment of central serous chorioretinopathy. Methods 72 cases (72 eyes) of CSC were randomly divided into two groups: control group (36 eyes, 36 eyes) and placebo vitamin C (0.1 g, 3 times a day). In the trial group, 36 cases (36 eyes) were treated with fenofibrate capsule 0.2 g, 3 times a day, 0.5 h before meals for 28 days. The visual acuity and fundus examination were compared before and after treatment. Results there was no significant difference in general conditions between the two groups (P 0.05). After 28 days of treatment, triglyceride was treated with triglyceride. There were statistically significant differences in the effects of low density lipoprotein (P 0.05), visual acuity improvement or no change in 53 eyes, Among them, 21 eyes of the control group were right and 32 eyes of the test group were 60.4%. The visual acuity of the two groups was significantly different from that of before treatment (蠂 2 8.651g P 0.05). The cure rate of the control group was 16.70.The total effective rate was 58.3%; the cure rate of the test group was 66.7%, the total effective rate was 88.9B; the total effective rate of the two groups was 88.9%; the difference of the total effective rate between the two groups was significant. Statistical significance (蠂 2 = 24.669), P0.05, 2 weeks and 4 weeks after treatment, 2 weeks and 4 weeks after treatment, 2 and 4 weeks after treatment, 2 and 4 weeks after treatment, The area of retinal detachment in the experimental group was reduced to 123,221 卤86.431 渭 m ~ (2) 渭 m ~ (2), 43 246 卤34 321) 渭 m ~ (2), which was larger than that in the control group (213,241 卤102,548) 渭 m ~ (2) 1521,245 卤87,326 渭 m ~ (2). The difference was statistically significant (P0.055.There was no adverse reaction between the two groups. Conclusion fenofibrate can improve the visual acuity of CSC patients. Effectively improve the symptoms of CSC, shorten the treatment time.
【作者单位】：南昌大学第一附属医院眼科;江西省萍乡市第二人民医院眼科;中南大学湘雅医院眼科;
【基金】：国家自然科学基金资助(编号:81160118、81160119、81100648、81100649、81170823、81160105、81101858) 全国临床医药研究专项基金资助(编号:L2012052) 江西省自然科学基金资助(编号:20114BAB215029) 江西省科技支撑计划项目(编号:20111BBG70026-2) 江西省卫生厅中医药科研项目(编号:2012A087) 江西省科技平台建设项目(编号:2013-116)~~
【分类号】：R774.1

【参考文献】